Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0450
+0.0020 (4.65%)
Feb 12, 2026, 3:51 PM EST

PVCT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-6.66-4.76-3.1-3.55-5.54-6.68
Depreciation & Amortization
00.010.010.010.010.24
Stock-Based Compensation
2.231.28000.020.13
Other Operating Activities
-0.020.050.050.050.020.07
Change in Accounts Receivable
00-00--
Change in Accounts Payable
-0.2-0.57-0.420.810.33-0.17
Change in Unearned Revenue
-0.35-0.62-0.56-0.992.5-
Change in Other Net Operating Assets
1.641.331.450.621.642.31
Operating Cash Flow
-3.37-3.28-2.57-3.04-1.01-4.09
Short-Term Debt Issued
---1.633.16-
Long-Term Debt Issued
-2.852.48--3.29
Total Debt Issued
2.082.852.481.633.163.29
Short-Term Debt Repaid
--0.31-0.28-0.26-0.25-0.11
Long-Term Debt Repaid
--0.1----
Total Debt Repaid
-0.25-0.41-0.28-0.26-0.25-0.11
Net Debt Issued (Repaid)
1.832.452.191.372.913.18
Issuance of Common Stock
----0.960.42
Other Financing Activities
10.3--0.15-
Financing Cash Flow
2.832.752.191.374.023.6
Foreign Exchange Rate Adjustments
-0-0-0.02-0-0-0.01
Net Cash Flow
-0.54-0.54-0.4-1.683.01-0.49
Free Cash Flow
-3.37-3.28-2.57-3.04-1.01-4.09
Free Cash Flow Margin
-961.21%-532.15%-461.17%-307.52%--
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.00-0.01
Levered Free Cash Flow
-0.63-2.93-1.16-0.88-6.941.06
Unlevered Free Cash Flow
-0.48-2.78-1.03-0.77-6.342.15
Change in Working Capital
1.080.140.470.454.472.14
Source: S&P Global Market Intelligence. Standard template. Financial Sources.